Immunogenicity and safety of COVID-19 BNT162b2 booster vaccine in end-stage kidney disease patients receiving haemodialysis in Yogyakarta, Indonesia: a cohort prospective study

Francis A(2021)The urgent need to vaccinate dialysis patients against severe acute respiratory syndrome coronavirus 2: a call to action Kidney Int 99 791-793

Baigent C(2023)Outcomes of vaccinations against respiratory diseases in patients with end-stage renal disease undergoing hemodialysis: a systematic review and meta-analysis PLoS ONE 18 11-12

Ikizler TA(2022)Breakthrough covid 19 infections after 2 doses of covid 19 vaccination and comparing severity between hospitalized and non hospitalized in tertiary care hospital J Assoc Physicians India 70 2212-2218

Cockwell P(2021)Vaccine breakthrough infections with SARS-CoV-2 variants N Engl J Med 384 137-139

Jha V(2022)Long-term antibody response to the BNT162b2 vaccine among maintenance hemodialysis patients Am J Kidney Dis 79 1103-1107

Puspitasari M(2022)Longevity and clinical effectiveness of the humoral and cellular responses to SARS-CoV-2 Vaccination in Hemodialysis Patients Kidney Int Reports 7 1-18

Sattwika PD(2022)Risk of strong antibody decline in dialysis and transplant patients after SARS-CoV-2mRNA vaccination: Six months data from the observational Dia-Vacc study Lancet Reg Heal - Eur 17 521-529

Rahari DS(2022)Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study Lancet 399 2524-2526

Wijaya W(2021)Durability of antibody levels after vaccination with mRNA SARS-CoV-2 vaccine in Individuals with or without prior infection JAMA 326 1633-1635

Hidayat ARP(2022)Humoral response after SARS-CoV-2 booster vaccination in haemodialysis patients with and without prior infection Clin Kidney J 15 1178-1181

Francis A(2021)The urgent need to vaccinate dialysis patients against severe acute respiratory syndrome coronavirus 2: a call to action Kidney Int 99 791-793

Baigent C(2023)Outcomes of vaccinations against respiratory diseases in patients with end-stage renal disease undergoing hemodialysis: a systematic review and meta-analysis PLoS ONE 18 11-12

Ikizler TA(2022)Breakthrough covid 19 infections after 2 doses of covid 19 vaccination and comparing severity between hospitalized and non hospitalized in tertiary care hospital J Assoc Physicians India 70 2212-2218

Cockwell P(2021)Vaccine breakthrough infections with SARS-CoV-2 variants N Engl J Med 384 137-139

Jha V(2022)Long-term antibody response to the BNT162b2 vaccine among maintenance hemodialysis patients Am J Kidney Dis 79 1103-1107

Puspitasari M(2022)Longevity and clinical effectiveness of the humoral and cellular responses to SARS-CoV-2 Vaccination in Hemodialysis Patients Kidney Int Reports 7 1-18

Sattwika PD(2022)Risk of strong antibody decline in dialysis and transplant patients after SARS-CoV-2mRNA vaccination: Six months data from the observational Dia-Vacc study Lancet Reg Heal - Eur 17 521-529

Rahari DS(2022)Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study Lancet 399 2524-2526

Wijaya W(2021)Durability of antibody levels after vaccination with mRNA SARS-CoV-2 vaccine in Individuals with or without prior infection JAMA 326 1633-1635

Hidayat ARP(2022)Humoral response after SARS-CoV-2 booster vaccination in haemodialysis patients with and without prior infection Clin Kidney J 15 1178-1181